Ontario, Canada-based Canntab Therapeutics Ltd., a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, will begin serving patients of Levitee Clinics Inc. in providing alternatives to treatment with opiates.
Levitee Clinics, a division of Vancouver, B.C.-based Levitee Labs, is establishing itself as a leader in the integrative wellness space served more than 35,000 patient visits in last 12 months. Levitee aims to transform mental health and addiction treatments through the integration of alternative medicinal therapies.
Levitee also operates three pharmacies in the Canadian province of Alberta specializing in filling prescriptions for patients with substance use disorders, mental health conditions and chronic pain.
Canntab’s full suite of oral tablet products, including a comprehensive range of both THC and CBD strengths, will be made available to Levitee and their patients. Both Canntab and Levitee believe that a hard tablet delivery format will be the preferred dosage format by many of Levitee’s patients, including more specifically the senior demographic and patients with several issues related to the use of opiates and other related painkillers.
In November, Canntab received its medical sales license from Health Canada, enabling the sale of its products directly to medical consumers. The amendment marked the final regulatory step required to launch the company’s direct to consumer website, allowing patients across Canada with an authorized medical document to immediately order online Canntab’s unique patented exact dosage tablets and caplets of THC and CBD in various strengths. Exact dosing and ease of administration are the key elements in the Canntab offering, which specifically addresses the needs of the medical community and patients.
“Canntab’s product offering is well suited to Levitee’s professional practitioners who want to prescribe CBD and/or THC for various therapies as part of their integrative health approach, general well-being as well as to address specific indications,” explained Larry Latowsky, Canntab’s CEO. “Our exact dosage THC and CBD products are best suited to meet the needs of the thousands of Levitee patients across the province of Alberta and beyond.”
Noha ElSayed, executive director for Levitee Clinics and Levitee Pharmacies in the Alberta Region, detailed how his company shares a vision with Canntab to play a meaningful role in flattening the curve of the opioid crisis in Canada by tapering use of addictive painkillers through the substitution of viable alternatives. Those alternatives can include cannabinoids like CBD and THC.
“Notwithstanding the lack of clinical trials for product specific uses, cannabinoids have shown great promise to provide patients relief for multiple indications in which we specialize,” said ElSayed. “I am eager for Canntab to begin servicing our pharmacies and clinics throughout Canada, as it will both drive additional revenue and better serve our patients.”
Canntab is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world.
